Integrative genomic approaches to understanding cancer

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 6, 2009, Pages 478-484

  Hahn, William C ^a,b,c   Dunn, Ian F ^a,b,c   Kim, So Young ^a,b,c   Schinzel, Anna C ^a,b,c   Firestein, Ron ^a,b,c   Guney, Isil ^a,b,c   Boehm, Jesse S ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Cancer; Genomic; Integration; Mutation

Indexed keywords

B RAF KINASE; BCR ABL PROTEIN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MICRORNA; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 6; PROTEIN BCL XL; PROTEIN P19; PROTEIN P53; RAS PROTEIN; RNA INDUCED SILENCING COMPLEX; SERINE PROTEINASE; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR ER81; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR NKX2.1; TRANSCRIPTION FACTOR PBX1; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR T BET; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; BRAIN CANCER; BREAST CANCER; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESEARCH; DRUG TARGETING; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; STOMACH CANCER;

GENE DOSAGE; GENOME, HUMAN; GENOMICS; HUMANS; MUTATION; NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 67349206589     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.02.003     Document Type: Review

References (79)

1. Chin L., and Gray J.W. Translating insights from the cancer genome into clinical practice. Nature 452 (2008) 553-563
2. Meister G., and Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 431 (2004) 343-349
3. Lamesch P., Li N., Milstein S., Fan C., Hao T., Szabo G., Hu Z., Venkatesan K., Bethel G., Martin P., Rogers J., Lawlor S., McLaren S., Dricot A., Borick H., Cusick M.E., Vandenhaute J., Dunham I., Hill D.E., and Vidal M. Human ORFeome 3.1: a resource of human open reading frames covering over 10,000 human genes. Genomics 89 (2007) 307-315
4. Rolfs A., Montor W.R., Yoon S.S., Hu Y., Bhullar B., Kelley F., McCarron S., Jepson D.A., Shen B., Taycher E., Mohr S.E., Zuo D., Williamson J., Mekalanos J., and Labaer J. Production and sequence validation of a complete full length ORF collection for the pathogenic bacterium Vibrio cholerae. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4364-4369
5. Karnoub A.E., and Weinberg R.A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell. Biol. 9 (2008) 517-531
6. Taya Y., Hosogai K., Hirohashi S., Shimosato Y., Tsuchiya R., Tsuchida N., Fushimi M., Sekiya T., and Nishimura S. A novel combination of K-ras and myc amplification accompanied by point mutational activation of K-ras in a human lung cancer. EMBO J. 3 (1984) 2943-2946
7. Downward J., Riehl R., Wu L., and Weinberg R.A. Identification of a nucleotide exchange-promoting activity for p21ras. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5998-6002
8. Futreal P.A., Coin L., Marshall M., Down T., Hubbard T., Wooster R., Rahman N., and Stratton M.R. A census of human cancer genes. Nat. Rev. Cancer 4 (2004) 177-183
9. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C., Shipley J., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A., Nicholson A., Ho J.W., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H., Marais R., Marshall C.J., Wooster R., Stratton M.R., and Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
10. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
11. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
12. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
13. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 13306-13311
14. George R.E., Sanda T., Hanna M., Frohling S., Luther II W., Zhang J., Ahn Y., Zhou W., London W.B., McGrady P., Xue L., Zozulya S., Gregor V.E., Webb T.R., Gray N.S., Gilliland D.G., Diller L., Greulich H., Morris S.W., Meyerson M., and Look A.T. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 (2008) 975-978
15. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., and Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
16. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008) 1801-1806
17. Leary R.J., Lin J.C., Cummins J., Boca S., Wood L.D., Parsons D.W., Jones S., Sjoblom T., Park B.H., Parsons R., Willis J., Dawson D., Willson J.K., Nikolskaya T., Nikolsky Y., Kopelovich L., Papadopoulos N., Pennacchio L.A., Wang T.L., Markowitz S.D., Parmigiani G., Kinzler K.W., Vogelstein B., and Velculescu V.E. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16224-16229
18. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Siu I.M., Gallia G.L., Olivi A., McLendon R., Rasheed B.A., Keir S., Nikolskaya T., Nikolsky Y., Busam D.A., Tekleab H., Diaz Jr. L.A., Hartigan J., Smith D.R., Strausberg R.L., Marie S.K., Shinjo S.M., Yan H., Riggins G.J., Bigner D.D., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., and Kinzler K.W. An integrated genomic analysis of human glioblastoma multiforme. Science 321 (2008) 1807-1812
19. Sjoblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K., Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W., and Velculescu V.E. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
20. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
21. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., Dooling D., Dunford-Shore B.H., McGrath S., Hickenbotham M., Cook L., Abbott R., Larson D.E., Koboldt D.C., Pohl C., Smith S., Hawkins A., Abbott S., Locke D., Hillier L.W., Miner T., Fulton L., Magrini V., Wylie T., Glasscock J., Conyers J., Sander N., Shi X., Osborne J.R., Minx P., Gordon D., Chinwalla A., Zhao Y., Ries R.E., Payton J.E., Westervelt P., Tomasson M.H., Watson M., Baty J., Ivanovich J., Heath S., Shannon W.D., Nagarajan R., Walter M.J., Link D.C., Graubert T.A., DiPersio J.F., and Wilson R.K. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456 (2008) 66-72
22. Bentley D.R., Balasubramanian S., Swerdlow H.P., Smith G.P., Milton J., Brown C.G., Hall K.P., Evers D.J., Barnes C.L., Bignell H.R., Boutell J.M., Bryant J., Carter R.J., Keira Cheetham R., Cox A.J., Ellis D.J., Flatbush M.R., Gormley N.A., Humphray S.J., Irving L.J., Karbelashvili M.S., Kirk S.M., Li H., Liu X., Maisinger K.S., Murray L.J., Obradovic B., Ost T., Parkinson M.L., Pratt M.R., Rasolonjatovo I.M., Reed M.T., Rigatti R., Rodighiero C., Ross M.T., Sabot A., Sankar S.V., Scally A., Schroth G.P., Smith M.E., Smith V.P., Spiridou A., Torrance P.E., Tzonev S.S., Vermaas E.H., Walter K., Wu X., Zhang L., Alam M.D., Anastasi C., Aniebo I.C., Bailey D.M., Bancarz I.R., Banerjee S., Barbour S.G., Baybayan P.A., Benoit V.A., Benson K.F., Bevis C., Black P.J., Boodhun A., Brennan J.S., Bridgham J.A., Brown R.C., Brown A.A., Buermann D.H., Bundu A.A., Burrows J.C., Carter N.P., Castillo N., Chiara E.C.M., Chang S., Neil Cooley R., Crake N.R., Dada O.O., Diakoumakos K.D., Dominguez-Fernandez B., Earnshaw D.J., Egbujor U.C., Elmore D.W., Etchin S.S., Ewan M.R., Fedurco M., Fraser L.J., Fuentes Fajardo K.V., Scott Furey W., George D., Gietzen K.J., Goddard C.P., Golda G.S., Granieri P.A., Green D.E., Gustafson D.L., Hansen N.F., Harnish K., Haudenschild C.D., Heyer N.I., Hims M.M., Ho J.T., Horgan A.M., Hoschler K., Hurwitz S., Ivanov D.V., Johnson M.Q., James T., Huw Jones T.A., Kang G.D., Kerelska T.H., Kersey A.D., Khrebtukova I., Kindwall A.P., Kingsbury Z., Kokko-Gonzales P.I., Kumar A., Laurent M.A., Lawley C.T., Lee S.E., Lee X., Liao A.K., Loch J.A., Lok M., Luo S., Mammen R.M., Martin J.W., McCauley P.G., McNitt P., Mehta P., Moon K.W., Mullens J.W., Newington T., Ning Z., Ling Ng B., Novo S.M., O'Neill M.J., Osborne M.A., Osnowski A., Ostadan O., Paraschos L.L., Pickering L., Pike A.C., Chris Pinkard D., Pliskin D.P., Podhasky J., Quijano V.J., Raczy C., Rae V.H., Rawlings S.R., Chiva Rodriguez A., Roe P.M., Rogers J., Rogert Bacigalupo M.C., Romanov N., Romieu A., Roth R.K., Rourke N.J., Ruediger S.T., Rusman E., Sanches-Kuiper R.M., Schenker M.R., Seoane J.M., Shaw R.J., Shiver M.K., Short S.W., Sizto N.L., Sluis J.P., Smith M.A., Ernest Sohna Sohna J., Spence E.J., Stevens K., Sutton N., Szajkowski L., Tregidgo C.L., Turcatti G., Vandevondele S., Verhovsky Y., Virk S.M., Wakelin S., Walcott G.C., Wang J., Worsley G.J., Yan J., Yau L., Zuerlein M., Mullikin J.C., Hurles M.E., McCooke N.J., West J.S., Oaks F.L., Lundberg P.L., Klenerman D., Durbin R., and Smith A.J. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456 (2008) 53-59
23. Thomas R.K., Nickerson E., Simons J.F., Janne P.A., Tengs T., Yuza Y., Garraway L.A., LaFramboise T., Lee J.C., Shah K., O'Neill K., Sasaki H., Lindeman N., Wong K.K., Borras A.M., Gutmann E.J., Dragnev K.H., Debiasi R.M., Chen T.H., Glatt K.A., Greulich H., Desany B., Lubenski C.K., Brockman W., Alvarez P., Hutchison S.K., Leamon J.H., Ronan M.T., Turenchalk G.S., Egholm M., Sellers W.R., Rothberg J.M., and Meyerson M. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat. Med. 12 (2006) 852-855
24. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., Ince W.L., Janne P.A., Januario T., Johnson D.H., Klein P., Miller V.A., Ostland M.A., Ramies D.A., Sebisanovic D., Stinson J.A., Zhang Y.R., Seshagiri S., and Hillan K.J. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. 23 (2005) 5900-5909
25. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., Lee J.C., Nicoletti R., Hatton C., Goyette M., Girard L., Majmudar K., Ziaugra L., Wong K.K., Gabriel S., Beroukhim R., Peyton M., Barretina J., Dutt A., Emery C., Greulich H., Shah K., Sasaki H., Gazdar A., Minna J., Armstrong S.A., Mellinghoff I.K., Hodi F.S., Dranoff G., Mischel P.S., Cloughesy T.F., Nelson S.F., Liau L.M., Mertz K., Rubin M.A., Moch H., Loda M., Catalona W., Fletcher J., Signoretti S., Kaye F., Anderson K.C., Demetri G.D., Dummer R., Wagner S., Herlyn M., Sellers W.R., Meyerson M., and Garraway L.A. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39 (2007) 347-351
26. Weir B., Zhao X., and Meyerson M. Somatic alterations in the human cancer genome. Cancer Cell 6 (2004) 433-438
27. Lucito R., Healy J., Alexander J., Reiner A., Esposito D., Chi M., Rodgers L., Brady A., Sebat J., Troge J., West J.A., Rostan S., Nguyen K.C., Powers S., Ye K.Q., Olshen A., Venkatraman E., Norton L., and Wigler M. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 13 (2003) 2291-2305
28. Albertson D.G., Collins C., McCormick F., and Gray J.W. Chromosome aberrations in solid tumors. Nat. Genet. 34 (2003) 369-376
29. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., Beheshti J., Lee J.C., Naoki K., Richards W.G., Sugarbaker D., Chen F., Rubin M.A., Janne P.A., Girard L., Minna J., Christiani D., Li C., Sellers W.R., and Meyerson M. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65 (2005) 5561-5570
30. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., Lin W.M., Province M.A., Kraja A., Johnson L.A., Shah K., Sato M., Thomas R.K., Barletta J.A., Borecki I.B., Broderick S., Chang A.C., Chiang D.Y., Chirieac L.R., Cho J., Fujii Y., Gazdar A.F., Giordano T., Greulich H., Hanna M., Johnson B.E., Kris M.G., Lash A., Lin L., Lindeman N., Mardis E.R., McPherson J.D., Minna J.D., Morgan M.B., Nadel M., Orringer M.B., Osborne J.R., Ozenberger B., Ramos A.H., Robinson J., Roth J.A., Rusch V., Sasaki H., Shepherd F., Sougnez C., Spitz M.R., Tsao M.S., Twomey D., Verhaak R.G., Weinstock G.M., Wheeler D.A., Winckler W., Yoshizawa A., Yu S., Zakowski M.F., Zhang Q., Beer D.G., Wistuba I.I., Watson M.A., Garraway L.A., Ladanyi M., Travis W.D., Pao W., Rubin M.A., Gabriel S.B., Gibbs R.A., Varmus H.E., Wilson R.K., Lander E.S., and Meyerson M. Characterizing the cancer genome in lung adenocarcinoma. Nature 450 (2007) 893-898
31. Yao J., Weremowicz S., Feng B., Gentleman R.C., Marks J.R., Gelman R., Brennan C., and Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 66 (2006) 4065-4078
32. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., Lee C., Wagner S.N., Li C., Golub T.R., Rimm D.L., Meyerson M.L., Fisher D.E., and Sellers W.R. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
33. Bussey K.J., Chin K., Lababidi S., Reimers M., Reinhold W.C., Kuo W.L., Gwadry F., Ajay, Kouros-Mehr H., Fridlyand J., Jain A., Collins C., Nishizuka S., Tonon G., Roschke A., Gehlhaus K., Kirsch I., Scudiero D.A., Gray J.W., and Weinstein J.N. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol. Cancer Ther. 5 (2006) 853-867
34. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., Sellers W.R., and Rosen N. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
35. Al-Kuraya K., Schraml P., Torhorst J., Tapia C., Zaharieva B., Novotny H., Spichtin H., Maurer R., Mirlacher M., Kochli O., Zuber M., Dieterich H., Mross F., Wilber K., Simon R., and Sauter G. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64 (2004) 8534-8540
36. Bergamaschi A., Kim Y.H., Wang P., Sorlie T., Hernandez-Boussard T., Lonning P.E., Tibshirani R., Borresen-Dale A.L., and Pollack J.R. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer 45 (2006) 1033-1040
37. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.L., Lapuk A., Neve R.M., Qian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Kingsley C., Dairkee S., Meng Z., Chew K., Pinkel D., Jain A., Ljung B.M., Esserman L., Albertson D.G., Waldman F.M., and Gray J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10 (2006) 529-541
38. Hicks J., Krasnitz A., Lakshmi B., Navin N.E., Riggs M., Leibu E., Esposito D., Alexander J., Troge J., Grubor V., Yoon S., Wigler M., Ye K., Borresen-Dale A.L., Naume B., Schlicting E., Norton L., Hagerstrom T., Skoog L., Auer G., Maner S., Lundin P., and Zetterberg A. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res. 16 (2006) 1465-1479
39. Beroukhim R., Getz G., Nghiemphu L., Barretina J., Hsueh T., Linhart D., Vivanco I., Lee J.C., Huang J.H., Alexander S., Du J., Kau T., Thomas R.K., Shah K., Soto H., Perner S., Prensner J., Debiasi R.M., Demichelis F., Hatton C., Rubin M.A., Garraway L.A., Nelson S.F., Liau L., Mischel P.S., Cloughesy T.F., Meyerson M., Golub T.A., Lander E.S., Mellinghoff I.K., and Sellers W.R. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20007-20012
40. Nucifora G., Birn D.J., Erickson P., Gao J., LeBeau M.M., Drabkin H.A., and Rowley J.D. Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 81 (1993) 883-888
41. Hunger S.P., Galili N., Carroll A.J., Crist W.M., Link M.P., and Cleary M.L. The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 77 (1991) 687-693
42. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., Fujiwara S., Watanabe H., Kurashina K., Hatanaka H., Bando M., Ohno S., Ishikawa Y., Aburatani H., Niki T., Sohara Y., Sugiyama Y., and Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 (2007) 561-566
43. Hanauer D.A., Rhodes D.R., Sinha-Kumar C., and Chinnaiyan A.M. Bioinformatics approaches in the study of cancer. Curr. Mol. Med. 7 (2007) 133-141
44. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., and Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648
45. Lin H.Y., Harris T.L., Flannery M.S., Aruffo A., Kaji E.H., Gorn A., Kolakowski Jr. L.F., Lodish H.F., and Goldring S.R. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254 (1991) 1022-1024
46. Seed B., and Aruffo A. Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3365-3369
47. Wang X.F., Lin H.Y., Ng-Eaton E., Downward J., Lodish H.F., and Weinberg R.A. Expression cloning and characterization of the TGF-beta type III receptor. Cell 67 (1991) 797-805
48. Koh E.Y., Chen T., and Daley G.Q. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30 (2002) e142
49. Jacobs J.J., Keblusek P., Robanus-Maandag E., Kristel P., Lingbeek M., Nederlof P.M., van Welsem T., van de Vijver M.J., Koh E.Y., Daley G.Q., and van Lohuizen M. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat. Genet. 26 (2000) 291-299
50. Peeper D.S., Shvarts A., Brummelkamp T., Douma S., Koh E.Y., Daley G.Q., and Bernards R. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat. Cell Biol. 4 (2002) 148-153
51. Shvarts A., Brummelkamp T.R., Scheeren F., Koh E., Daley G.Q., Spits H., and Bernards R. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev. 16 (2002) 681-686
52. Huang Q., Raya A., DeJesus P., Chao S.H., Quon K.C., Caldwell J.S., Chanda S.K., Izpisua-Belmonte J.C., and Schultz P.G. Identification of p53 regulators by genome-wide functional analysis. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3456-3461
53. Gunawardane R.N., Sgroi D.C., Wrobel C.N., Koh E., Daley G.Q., and Brugge J.S. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res. 65 (2005) 11572-11580
54. Martin S.S., Ridgeway A.G., Pinkas J., Lu Y., Reginato M.J., Koh E.Y., Michelman M., Daley G.Q., Brugge J.S., and Leder P. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 23 (2004) 4641-4645
55. Boehm J.S., Zhao J.J., Yao J., Kim S.Y., Firestein R., Dunn I.F., Sjostrom S.K., Garraway L.A., Weremowicz S., Richardson A., Greulich H., Stewart C.J., Mulvey L.A., Shen R.R., Ambrogio L., Hirozane-Kishikawa T., Hill D.E., Vidal M., Meyerson M., Grenier J.K., Hinkle G., Root D.E., Roberts T.M., Lander E.S., Polyak K., and Hahn W.C. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129 (2007) 1065-1079
56. Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol. Biol. 342 (2006) 129-138
57. Johnson B.E., and Janne P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65 (2005) 7525-7529
58. He L., Thomson J.M., Hemann M.T., Hernando-Monge E., Mu D., Goodson S., Powers S., Cordon-Cardo C., Lowe S.W., Hannon G.J., and Hammond S.M. A microRNA polycistron as a potential human oncogene. Nature 435 (2005) 828-833
59. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., and Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13944-13949
60. Kumar M.S., Lu J., Mercer K.L., Golub T.R., and Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39 (2007) 673-677
61. Voorhoeve P.M., le Sage C., Schrier M., Gillis A.J., Stoop H., Nagel R., Liu Y.P., van Duijse J., Drost J., Griekspoor A., Zlotorynski E., Yabuta N., De Vita G., Nojima H., Looijenga L.H., and Agami R. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124 (2006) 1169-1181
62. Bernstein E., Caudy A.A., Hammond S.M., and Hannon G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409 (2001) 363-366
63. Dykxhoorn D.M., Novina C.D., and Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell. Biol. 4 (2003) 457-467
64. Root D.E., Hacohen N., Hahn W.C., Lander E.S., and Sabatini D.M. Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat. Methods 3 (2006) 715-719
65. Aza-Blanc P., Cooper C.L., Wagner K., Batalov S., Deveraux Q.L., and Cooke M.P. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol. Cell. 12 (2003) 627-637
66. Kittler R., and Buchholz F. Functional genomic analysis of cell division by endoribonuclease-prepared siRNAs. Cell Cycle 4 (2005) 564-567
67. MacKeigan J.P., Murphy L.O., and Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7 (2005) 591-600
68. Whitehurst A.W., Bodemann B.O., Cardenas J., Ferguson D., Girard L., Peyton M., Minna J.D., Michnoff C., Hao W., Roth M.G., Xie X.J., and White M.A. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446 (2007) 815-819
69. Kolfschoten I.G., van Leeuwen B., Berns K., Mullenders J., Beijersbergen R.L., Bernards R., Voorhoeve P.M., and Agami R. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121 (2005) 849-858
70. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., Zhao J.J., Roberts T.M., Mandel G., Hannon G.J., Depinho R.A., Chin L., and Elledge S.J. A genetic screen for candidate tumor suppressors identifies REST. Cell 121 (2005) 837-848
71. Firestein R., Bass A.J., Kim S.Y., Dunn I.F., Silver S.J., Guney I., Freed E., Ligon A.H., Vena N., Ogino S., Chheda M.G., Tamayo P., Finn S., Shrestha Y., Boehm J.S., Jain S., Bojarski E., Mermel C., Barretina J., Chan J.A., Baselga J., Tabernero J., Root D.E., Fuchs C.S., Loda M., Shivdasani R.A., Meyerson M., and Hahn W.C. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 455 (2008) 547-551
72. Jones T.R., Kang I.H., Wheeler D.B., Lindquist R.A., Papallo A., Sabatini D.M., Golland P., and Carpenter A.E. CellProfiler Analyst: data exploration and analysis software for complex image-based screens. BMC Bioinformatics 9 (2008) 482
73. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., Carpenter A.E., Foo S.Y., Stewart S.A., Stockwell B.R., Hacohen N., Hahn W.C., Lander E.S., Sabatini D.M., and Root D.E. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
74. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., and Staudt L.M. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441 (2006) 106-110
75. Schrock E., du Manoir S., Veldman T., Schoell B., Wienberg J., Ferguson-Smith M.A., Ning Y., Ledbetter D.H., Bar-Am I., Soenksen D., Garini Y., and Ried T. Multicolor spectral karyotyping of human chromosomes. Science 273 (1996) 494-497
76. Brummelkamp T.R., Fabius A.W., Mullenders J., Madiredjo M., Velds A., Kerkhoven R.M., Bernards R., and Beijersbergen R.L. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat. Chem. Biol. 2 (2006) 202-206
77. Luo B., Cheung H.W., Subramanian A., Sharifnia T., Okamoto M., Yang X., Hinkle G., Boehm J.S., Beroukhim R., Weir B.A., Mermel C., Barbie D.A., Awad T., Zhou X., Nguyen T., Piqani B., Li C., Golub T.R., Meyerson M., Hacohen N., Hahn W.C., Lander E.S., Sabatini D.M., and Root D.E. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 20380-20385
78. Zender L., Xue W., Zuber J., Semighini C.P., Krasnitz A., Ma B., Zender P., Kubicka S., Luk J.M., Schirmacher P., McCombie W.R., Wigler M., Hicks J., Hannon G.J., Powers S., and Lowe S.W. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell 135 (2008) 852-864
79. Plass C. Cancer epigenomics. Hum. Mol. Genet. 11 (2002) 2479-2488